Augmenix

Category Archives

Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018

First and only prostate cancer spacing device available for use in the U.S. clinically proven to preserve patient quality of life following radiation therapy BEDFORD, Read more...

Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy Of Spaceoar Hydrogel In Patients Undergoing Dose-Escalated Stereotactic Body Radiation Therapy For Prostate Cancer

Application of SpaceOAR hydrogel significantly reduces rectal injury in a high-dose SBRT treated patient population BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...

Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology

BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that Read more...

Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year

Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500 BEDFORD, Read more...

Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada

Princess Margaret Cancer Centre to initiate a 20-patient pilot study to assess hydrogel spacer to reduce rectal toxicity during prostate cancer radiation Read more...

Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment

Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...

Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that Read more...

Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material

The CPT Code establishes a standard reimbursement pathway for this new procedure which is performed with SpaceOAR®technology WALTHAM, Mass.--(BUSINESS Read more...

Augmenix Ranked as One of America’s Fastest-Growing Private Companies

Augmenix Ranked as One of America’s Fastest-Growing Private Companies With a Three-Year Sales Growth of 643%, Augmenix is one of the Fastest Growing Read more...

Augmenix raises $6m in Series E round

Augmenix said today it raised $6 million in a Series E round of funding to support the development of next-gen products and support the Read more...

Page 1 of 3123

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184